The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center, discusses the implications from the phase III MONALEESA-3 trial for postmenopausal women with HR+ and HER2 negative advanced breast cancer
Tags: ESMO 2019
Published: 11 October 2019
David Quinn, MD, explains the impact of data being presented at ASCO GU20 regarding neoadjuvant bladder cancer
Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, explains the impact of data being presented at ASCO ...
David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients
Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, discuses best utilization of stereotactic radiation in the management ...
David Quinn, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in advanced renal cell carcinoma patients
Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, on the results of long term follow up of ...
David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma
Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, describes whether biomarkers are able to aid in guiding ...
Scott Tawaga, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive non muscle invasive bladder cancer
Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares perspective on the study ...
Scott Tawaga, MD, explains intravesical therapies being developed given there is a BCG shortage
Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, explains intravesical therapies being developed ...
Scott Tawaga, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients
Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares results of phase 1 ...
Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients
Dr. Zhang, Assistant Professor of Medicine, Duke University School of Medicine, shares results of the 5 year follow up of ...
Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O
Dr. McGregor, Clinical Director, Dana Farber Cancer Institute, discusses strategy when treating metastatic renal cell cancer patients whose cancer returns ...
Nicolas Salgia, BSc, on ways ethnicity impacts 1st line metastatic renal cell carcinoma patients receiving targeted therapy
Dr. Salgia, BSc, City of Hope, on the impact of ethnicity on outcomes in 1st line metastatic renal cell carcinoma ...
Follow @OBRTweets